Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
NCT ID: NCT03653208
Last Updated: 2021-04-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
56 participants
INTERVENTIONAL
2018-11-20
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
NCT04817202
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug
NCT05234320
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
NCT01756131
Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
NCT02151110
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT07205796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (hzVSF-v13 10mg)
Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 2 (hzVSF-v13 20mg)
Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 3 (hzVSF-v13 50mg)
Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 4 (hzVSF-v13 100mg)
Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 5 (hzVSF-v13 200mg)
Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 6 (hzVSF-v13 400mg)
Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 7 (hzVSF-v13 800mg)
Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Group 8 (hzVSF-v13 1200mg)
Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Placebo
Placebo group received a single placebo on Day 1.
Placebo
Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hzVSF-v13
Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Placebo
Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals with a BMI of at least 18 kg/m2 and up to 27.0 kg/m2 weighed more than 55 kg and less than 90 kg at the time of the screening visit
* Individuals deemed clinically healthy based on medical history, physical examination, vital signs, electrocardiography (ECG), and appropriate clinical laboratory tests (provided that individuals outside the normal range may participate subject to investigator discretion)
* Individuals who have agreed to use a medically acceptable method of dual contraception and not to donate sperm from the first day until 30 days after the last day of investigational product administration
* Individuals who have voluntarily decided to participate in this clinical study and have given written consent to comply with the requirements of the study
Exclusion Criteria
* Individuals with a clinically significant history of sensitivity to the components of hzVSF-v13, drugs containing components of the same series, or other drugs (aspirin, non-steroidal anti-inflammatory drugs, antibiotics, etc.)
* Individuals testing positive in the immunogenicity test for hzVSF-v13 conducted during screening
* Individuals who have a history of drug abuse, or who turns out "positive" in test for abuse-likely drugs in the urine drug screening test
* Individuals with abnormal results for any of the following vital signs at the time of the screening visit A. Systolic blood pressure: \< 90 mmHg or \> 140 mmHg B. Diastolic blood pressure: \< 50 mmHg or \> 90 mmHg C. Heart rate: \< 50 bpm or \> 90 bpm
* Individuals with abnormal results for any of the following ECG items at the time of the screening visit A. PR (Pulse rate): \> 210 msec B. QRS complex : \> 120 msec \* QRS complex is the name for the combination of three of the graphical deflections seen on a typical electrocardiogram (EKG or ECG) C. QTc (Corrected QT interval): \> 450 msec
* Individuals who have participated in another clinical study or bioequivalence study in the 3 months prior to the first day of administration
* Individuals who have donated whole blood within the 2 months prior to the first day of administration, or donated blood components or received blood within the 1 month prior to the first day of administration
* Individuals who have taken barbitals or other drug-metabolizing enzyme inducers or inhibitors within the 1 month prior to screening
* Individuals who have consumed grapefruit or caffeine-containing foods within 3 days of the first administration, and individuals who are unable to avoid consuming grapefruit-containing foods from 3 days prior to admission until the date of discharge
* Individuals who have taken prescription drugs or oriental medications within 2 weeks prior to the first day of administration, or who have taken over-the-counter (OTC) drugs within the 1 week prior to the first day of administration (provided that individuals who meet other requirements may participate in the clinical study subject to investigator discretion)
* Individuals who consume high amounts of caffeine or alcohol and individuals who are heavy smokers (caffeine \> 5 units/day, alcohol \> 21 units/week (1 unit = 10 mL of pure alcohol), smoking \> 10 cigarettes/day)
* Individuals who are unable to eat meals provided by the institution
* Individuals who have participated in the present study
* Individuals who test positive (for hepatitis B, human immunodeficiency virus (HIV), hepatitis C) on serological testing
* Individuals with veins that are not suitable for intravenous catheter insertion or multiple venipunctures
* Individuals who do not agree to use a medically acceptable method of dual contraception from the first day until 30 days after the last day of investigational product administration
* Other individuals deemed unsuitable as a subject by an investigator
19 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmuneMed, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
In-Jin Jang, M.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University College of Medicine/Seoul National University Hospital Department of Clinical Pharmacology and Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM_hzVSF_v13-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.